Avunduk A M, Avunduk M C, Kapicioglu Z, Akyol N, Tavli L
Department of Ophthalmology, Karadeniz Technical University School of Medicine, Trabzon, Turkey.
Ophthalmology. 2000 Jul;107(7):1333-7. doi: 10.1016/s0161-6420(00)00089-0.
To explore the mechanism of action of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis (VKC) and to compare the efficacy of these drugs to each other.
Single-investigator, masked, randomized, clinical trial.
Twenty male and 10 female patients between the ages of 6 and 19 years, who were diagnosed as having active VKC, were enrolled in this study.
The patients were randomly divided into two equal groups (groups A and B). Group A patients received topical lodoxamide ophthalmic solution 0.1% (LOS); topical cromolyn sodium ophthalmic solution 4% (CSO) was prescribed to group B patients in a dose of two drops four times daily.
The eye symptom severity scores and clinical signs of the patients were evaluated both in the pre- and post-treatment periods. In addition to the clinical data, conjunctival impression cytologic specimens were obtained from patients both before and after treatment. Impression cytologic specimens were stained using immunohistochemical methods to detect the percentages of CD4(+), CD8(+), CD45RA(+), and CD23(+) cells. Statistical analyses were performed within and between groups.
The percentages of CD4(+) and CD23(+) cells in tear samples of patients in groups A and B were significantly higher in the pretreatment stage than post-treatment stage. In the post-treatment stage, group A patients had significantly lower CD4(+) and CD23(+) cell values compared with group B patients. Patient symptom scores and clinical signs were at a significantly lower level after treatment with either LOS or CSO in both groups A and B compared with their pretreatment values. Moreover, group A patients had significantly lower symptom scores and clinical signs than group B patients in the post-treatment stage.
Clinical superiority of LOS over CSO may be linked to its greater effect on the CD4(+) cells, because CD4(+) cells plays a pivotal role in the pathogenesis of VKC.
探讨局部用洛度沙胺和色甘酸钠治疗春季角结膜炎(VKC)的作用机制,并比较这两种药物的疗效。
单研究者、盲法、随机临床试验。
20名男性和10名女性患者,年龄在6至19岁之间,被诊断为患有活动性VKC,纳入本研究。
患者被随机分为两组(A组和B组),每组人数相等。A组患者接受0.1%洛度沙胺滴眼液(LOS);B组患者使用4%色甘酸钠滴眼液(CSO),每日4次,每次2滴。
在治疗前和治疗后评估患者的眼部症状严重程度评分和临床体征。除临床数据外,在治疗前后均从患者处获取结膜印片细胞学标本。使用免疫组织化学方法对印片细胞学标本进行染色,以检测CD4(+)、CD8(+)、CD45RA(+)和CD23(+)细胞的百分比。在组内和组间进行统计分析。
A组和B组患者泪液样本中CD4(+)和CD23(+)细胞的百分比在治疗前阶段显著高于治疗后阶段。在治疗后阶段,A组患者的CD4(+)和CD23(+)细胞值显著低于B组患者。与治疗前值相比,A组和B组患者在使用LOS或CSO治疗后,患者症状评分和临床体征均显著降低。此外,在治疗后阶段,A组患者的症状评分和临床体征显著低于B组患者。
LOS在临床上优于CSO可能与其对CD4(+)细胞的更大作用有关,因为CD4(+)细胞在VKC的发病机制中起关键作用。